Retatrutide, a new dual stimulator of the GLP-1 target and glucose-dependent insulinotropic polypeptide (GIP) receptor , is demonstrating promising results in preliminary human studies. Recent research https://bookmarkforest.com/story21286037/retatrutide-emerging-research-and-possible-clinical-roles